News and Events

Cell surface molecule could predict how patients respond to immunotherapy

A new study finds that some immunotherapy drugs are less likely to control cancer in patients who carry HLA-A*03, a cell surface molecule that is involved in immune system responses. This work, which was featured in NCI's Cancer Currents, reveals that HLA-A*03 is a potential biomarker for patient prognosis following certain immunotherapy treatments.

Clinical trial researches drug combination with immunotherapy for mesothelioma

Mesothelioma is a rare, fast-growing cancer that forms in membranes that surround and protect the heart, lungs and abdomen. The cells of malignant mesothelioma express large amounts of mesothelin, a cancerous protein. Investigators are researching a mesothelin-targeting drug in combination with immunotherapy.

GPC3 expression in hepatocellular carcinoma

Clinical trial targets cell surface protein GPC3 to treat advanced hepatocellular carcinoma

Tim F. Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, is leading a study of advanced hepatocellular carcinoma, a common type of liver cancer with a poor prognosis. The research uses CAR T-cell therapy to target GPC3-positive tumor cells while avoiding healthy tissue.

artist depiction of a tumor microenvironment

CCR researchers use immunogenetic profiling to identify targets for numerous pediatric cancers

Researchers analyzed over 700 pediatric tumor samples and cell lines, creating one of the largest profile datasets of gene expression and immune response in solid pediatric tumors to date. Their work reveals that a germline developmental protein called PRAME is a potential cancer target.

Anish Thomas explains the challenges and goals of his small cell lung cancer research

Anish Thomas, M.B.B.S., M.D., Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, studies small cell lung cancer (SCLC). For Lung Cancer Awareness Month, Thomas describes his current research interests and his goals to help improve the lives of patients with SCLC – the most lethal type of lung cancer.

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

New evidence suggests that adding the drug ibrutinib to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live. The findings come from a new analysis led by Louis M. Staudt, M.D., Ph.D., Chief of the Lymphoid Malignancies Branch, of a previous phase III clinical trial.

Clinical trial studies breast cancer drug abemaciclib as a therapy for Kaposi sarcoma

Kaposi sarcoma (KS) is a rare cancer that causes patches of abnormal tissue to develop in different regions of the body, and lesions in the lungs, liver, or digestive tract can be life-threatening. Investigators are studying abemaciclib, a drug used for people with breast cancer, to see if it can positively impact those with KS.

Rosenberg, Waldmann named 2021 Fellows of the Academy of Immuno-Oncology

Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, and Thomas A. Waldmann, M.D., Chief Emeritus of the Lymphoid Malignancies Branch (honored posthumously), have been named 2021 Fellows of the Academy of Immuno-Oncology, one of the most prestigious honors from the Society for Immunotherapy of Cancer (SITC). The Academy of Immuno-Oncology was established to honor individuals who have launched the field of cancer immunotherapy into the breakthrough cancer treatment it is today and to bring together the brightest minds in the field to continue to advance SITC, the field and the next generation of immuno-oncologists.

Gut bacteria sculpt innate immunity within the tumor microenvironment

New research reveals how gut bacteria reprogram innate immune cells to activate and recruit cells important for anti-cancer immunity, keeping tumor growth in check and improving the response to cancer immunotherapy.

A conversation with Hunter Lab members about the Deaf Student Training Program

Kent W. Hunter, Ph.D., Senior Investigator in the Laboratory of Cancer Biology and Genetics, leads the Deaf Student Training Program (DSTP) for budding scientists who are deaf or hard-of-hearing. In honor of National Disability Employment Awareness Month, DSTP participants talk about their experiences in the program, and Dr. Hunter offers his thoughts as a cancer researcher and disability ally.

Breadcrumb